Fig. 5: Validation of prior results by PARP1 and RAD51 protein expression. | Nature Communications

Fig. 5: Validation of prior results by PARP1 and RAD51 protein expression.

From: Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers

Fig. 5

a PARP1 nuclear positivity (average tumor H-score) by tumor type, for 23 tumors in tissue microarrays. NS not significant. b PARP1 nuclear positivity (average tumor H-score) by PARP1 copy number status across all tumors. For a and b, groupwise differences were assessed by Kruskal–Wallis test, followed by Dunn’s test with Bonferroni correction (α = 0.05). c Percent of RAD51+ cells in primary (n = 3) and recurrent (n = 4) breast tumors based on BRCA2 transcript usage. d Percent of RAD51+ cells in primary (n = 6) and recurrent (n = 7) ovarian tumors based on BRCA2 transcript usage. For c and d, boxplot elements are as follows: median, center line; box limits, first and third quartiles (spanning the IQR, interquartile range); whiskers, 1.5x IQR in each direction; outliers plotted individually. Groupwise differences in c and d were assessed by two-sided Wilcoxon rank sum test (α = 0.05). Tumors without RNA-seq data (n = 2) or expressing both BRCA2 isoforms (n = 1) were excluded from this analysis.

Back to article page